These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15238772)

  • 1. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing.
    Lucas GM; Gallant JE; Moore RD
    AIDS; 2004 Jul; 18(11):1539-48. PubMed ID: 15238772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
    Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
    PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reporting on the prevalence of antiretroviral drug resistance in a regional HIV population over 20 years: a word of caution.
    Gill VC; Lynch T; Ramazani S; Krentz HB
    Antivir Ther; 2017; 22(4):277-286. PubMed ID: 27805572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.
    Darwich L; Esteve A; Ruiz L; Paredes R; Bellido R; Cabrera C; Romeu J; Bofill M; Clotet B; Martinez-Picado J
    AIDS Res Hum Retroviruses; 2008 May; 24(5):725-32. PubMed ID: 18462084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa.
    Seyler C; Adjé-Touré C; Messou E; Dakoury-Dogbo N; Rouet F; Gabillard D; Nolan M; Toure S; Anglaret X
    AIDS; 2007 May; 21(9):1157-64. PubMed ID: 17502726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.
    Sterling TR; Chaisson RE; Moore RD
    AIDS; 2001 Nov; 15(17):2251-7. PubMed ID: 11698698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.
    Castor D; Vlahov D; Hoover DR; Berkman A; Wu YF; Zeller B; Brechtl J; Hammer SM
    J Med Virol; 2009 Aug; 81(8):1323-35. PubMed ID: 19551816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients.
    Zaccarelli M; Tozzi V; Lorenzini P; Trotta MP; Forbici F; Visco-Comandini U; Gori C; Narciso P; Perno CF; Antinori A;
    AIDS; 2005 Jul; 19(10):1081-9. PubMed ID: 15958840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads.
    Kieffer TL; Finucane MM; Nettles RE; Quinn TC; Broman KW; Ray SC; Persaud D; Siliciano RF
    J Infect Dis; 2004 Apr; 189(8):1452-65. PubMed ID: 15073683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus type 1 infection in Oman: antiretroviral therapy and frequencies of drug resistance mutations.
    Al Dhahry SH; Scrimgeour EM; Al Suwaid AR; Al Lawati MR; El Khatim HS; Al Kobaisi MF; Merigan TC
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1166-72. PubMed ID: 15588338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
    Nettles RE; Kieffer TL; Kwon P; Monie D; Han Y; Parsons T; Cofrancesco J; Gallant JE; Quinn TC; Jackson B; Flexner C; Carson K; Ray S; Persaud D; Siliciano RF
    JAMA; 2005 Feb; 293(7):817-29. PubMed ID: 15713771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.
    Baxter JD; Mayers DL; Wentworth DN; Neaton JD; Hoover ML; Winters MA; Mannheimer SB; Thompson MA; Abrams DI; Brizz BJ; Ioannidis JP; Merigan TC
    AIDS; 2000 Jun; 14(9):F83-93. PubMed ID: 10894268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
    Han XX; Zhang M; Cui WG; Liu BG; Wang Yn; Zhang ZN; Liu J; Geng WQ; Diao YY; Dai D; Jiang YJ; Shang H
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):760-4. PubMed ID: 15949383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency of drug resistance mutations in human immunodeficiency virus type 1-infected Korean patients treated with HAART.
    Sung H; Jung YS; Kang MW; Bae IG; Chang HH; Woo JH; Cho YK
    AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1223-9. PubMed ID: 17961108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.